Tibsovo (Ivosidenib) 250mg Tablets — IDH1 Inhibitor for AML & Cholangiocarcinoma | USA | GLT

Generic Information: Tibsovo (Ivosidenib) — United States Reference Product

This listing is the United States originator version of Tibsovo (ivosidenib), the first-in-class oral inhibitor of mutated IDH1 developed by Agios Pharmaceuticals and marketed in the US today by Servier Pharmaceuticals, which acquired Agios' oncology portfolio. The US bottle shown carries NDC 71334-100-01 — 60 film-coated 250 mg tablets, dispensed with a Medication Guide under federal "Rx only" rules. For buyers comparing ivosidenib sources worldwide, the US product is the regulatory reference against which the China version and every generic are measured.

Ivosidenib was the first medicine ever approved against a metabolic enzyme mutation in blood cancer, and it remains the only drug of its kind: no other marketed therapy touches the IDH1 target.

What Is US Tibsovo (Ivosidenib)?

Each white, high-density polyethylene bottle contains sixty 250 mg tablets of ivosidenib — a standard one-month oral course at the approved once-daily dose. The tablets are blue, oval, and film-coated, imprinted to distinguish strength and prevent counterfeiting. As the US commercial presentation, this version follows the FDA label in full, including boxed-warning-level guidance on differentiation syndrome and QTc prolongation, and it ships with the patient Medication Guide that US law requires.

How Does Tibsovo (Ivosidenib) Target IDH1?

In a subset of AML and cholangiocarcinoma patients, a mutation in the IDH1 gene warps the enzyme's chemistry so it manufactures 2-hydroxyglutarate (2-HG), a metabolite that epigenetically freezes blood-forming cells in an immature, endlessly dividing state. Ivosidenib selectively inhibits the mutant enzyme, and 2-HG levels collapse within days of the first dose. Freed from the metabolic brake, leukemic blasts resume normal maturation and die off through the body's own differentiation machinery. This is fundamentally different from chemotherapy: it corrects a specific molecular fault rather than poisoning all dividing cells.

FDA-Approved Indications for Tibsovo

• Adults with relapsed or refractory AML carrying a susceptible IDH1 mutation.
• Adults with newly diagnosed IDH1-mutated AML who are 75 years or older, or who have comorbidities precluding intensive induction chemotherapy — in combination with azacitidine.
• Adults with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation, identified by an FDA-approved companion diagnostic.

Dosage and Administration of US Tibsovo

The recommended dose across all approved uses is 250 mg orally once daily until disease progression or unacceptable toxicity. Tablets are swallowed whole — never split, crushed, or chewed — at about the same time each day, with or without food but not alongside a high-fat meal. The label details dose modifications for QTc prolongation (baseline and serial ECGs plus electrolyte monitoring are mandatory) and for differentiation syndrome, which is managed with corticosteroids and hemodynamic support. Strong CYP3A4 inducers are avoided, and combined P-gp/strong CYP3A4 inhibitors require dose caution.

Side Effects Profile of Ivosidenib

Across the US trials and post-marketing experience, the commonest reactions are fatigue, leukopenia, neutropenia, diarrhea, edema, nausea, vomiting, stomatitis, abdominal pain, and electrocardiographic QT prolongation. Two risks carry explicit label warnings: differentiation syndrome (fever, dyspnea, hypoxia, weight gain) and QTc prolongation with potential arrhythmia. Laboratory monitoring — weekly CBC and chemistry during the early cycles — plus ECG surveillance is standard practice, and patients are counseled to report fever or breathlessness immediately.

Storage of Tibsovo Bottles

Keep the bottle tightly closed at 20°C–25°C (68°F–77°F), with excursions allowed between 15°C and 30°C. Protect from moisture and light, keep out of reach of children, and do not use beyond the expiration date printed on the cap seal. Ambient shipping is appropriate for this product; no cold chain is required.

Why Choose GLT for US Sourcing?

The US originator is a high-value specialty medicine, and sourcing it from outside the United States is rarely straightforward. GIVE LIFE TIME LIMITED (GLT) helps institutional buyers and individual patients evaluate the full ivosidenib landscape — the US reference product, the identical China-approved originator, and quality generics from Laos — so each buyer can weigh regulatory status, budget, and urgency on real information. Every US-sourced order is verified for NDC, lot traceability, and intact packaging before dispatch.

How to Order Tibsovo from the United States

To order the US version of Tibsovo, or to compare it against the China originator and Laos generics before committing, contact GIVE LIFE TIME LIMITED (GLT) on WhatsApp at +86 15234153837 or by email at [email protected]. We work with hospital procurement teams, licensed wholesalers, physician buyers, and individual patients, and we quote documentation, pricing, and shipping timelines case by case.

FAQ: US Tibsovo

Q: Who sells Tibsovo in the United States today?
A: Servier Pharmaceuticals — the group acquired Agios' oncology business, including ivosidenib, and continues to market the product under the original brand.

Q: What is the NDC for the 60-tablet bottle?
A: NDC 71334-100-01 identifies the US 250 mg bottle of 60 tablets dispensed with a Medication Guide.

Q: Does the US label cover anything the China label does not?
A: Yes. Beyond R/R AML, the FDA label also covers newly diagnosed IDH1-mutated AML with azacitidine and previously treated IDH1-mutated cholangiocarcinoma.

Q: Is a generic ivosidenib available?
A: Not in the US market; quality generics currently come from manufacturers in Laos, which GLT can source alongside the originator.

Q: How do I order?
A: Contact GLT on WhatsApp +86 15234153837 or email [email protected] to discuss availability and shipping.